{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:26:31Z","timestamp":1787019991317,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["T32NS007413"],"award-info":[{"award-number":["T32NS007413"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016499","name":"Rett Syndrome Research Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016499","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009633","name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development","doi-asserted-by":"publisher","award":["U54HD08321"],"award-info":[{"award-number":["U54HD08321"]}],"id":[{"id":"10.13039\/100009633","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002243"],"award-info":[{"award-number":["UL1TR002243"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurodevelop Disord"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preclinical studies and anecdotal case reports support the potential therapeutic benefit of low-dose oral ketamine as a treatment of clinical symptoms in Rett syndrome (RTT); however, no controlled studies have been conducted in RTT to evaluate safety, tolerability and efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>This was a sequentially initiated, dose-escalating cohort, placebo-controlled, double blind, randomized sequence, cross-over study of oral ketamine in 6\u201312-year-old girls with RTT to evaluate short-term safety and tolerability and explore efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants were randomized to either five days treatment with oral ketamine or matched placebo, followed by a nine-day wash-out period and then crossed-over to the opposite treatment. Ketamine was dosed twice daily at 0.75\u00a0mg\/kg\/dose (Cohort 1) or 1.5\u00a0mg\/kg\/dose (Cohort 2). An independent safety monitoring committee evaluated safety and approved proceeding to the next dose cohort. Caregivers, participants, outcome assessors, and study staff except pharmacists were blinded to allocation. The primary endpoint was safety and tolerability. Exploratory efficacy endpoints included change in clinician- and caregiver-rated measures of RTT features, brain activity on electroencephalography, and wearable biosensors to measure respiration, heart rate, sleep, and activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-three participants enrolled (11 in Cohort 1, 12 in Cohort 2) from 3\/12\/2019\u201311\/22\/2021. One participant was excluded from analysis due to not meeting inclusion criteria on blinded review prior to analysis. One participant was withdrawn from the study due to an adverse event (vomiting) after the first dose of ketamine. Although planned for four dose cohorts, the trial was stopped after Cohort 2 due to enrollment challenges associated with the COVID-19 pandemic. Ketamine was safe and tolerated in both cohorts, with 1 related treatment emergent adverse event of vomiting. No difference was observed in efficacy between ketamine and placebo. Electroencephalography showed the expected increase in high frequency power with ketamine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Short-term, low-dose oral ketamine was safe and well tolerated in girls with RTT. No clinical efficacy of ketamine in treating symptoms of RTT was observed with 5\u00a0days of treatment, despite electroencephalography evidence of ketamine target engagement during the first dose. Further studies are needed to evaluate safety and efficacy of higher dose and longer exposure to ketamine in RTT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>Registered at clinicaltrials.gov NCT03633058.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s11689-025-09591-y","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:14:58Z","timestamp":1737692098000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A randomized, placebo-controlled, cross-over trial of ketamine in Rett syndrome"],"prefix":"10.1186","volume":"17","author":[{"given":"Kathleen","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Neul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David N.","family":"Lieberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Berry-Kravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim A.","family":"Benke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Percy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Suter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall L.","family":"Carpenter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"von Hehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"issue":"6","key":"9591_CR1","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/ana.22124","volume":"68","author":"JL Neul","year":"2010","unstructured":"Neul JL, Kaufmann WE, Glaze DG, Christodoulou J, Clarke AJ, Bahi-Buisson N, et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944\u201350.","journal-title":"Ann Neurol"},{"issue":"1","key":"9591_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s11689-023-09502-z","volume":"15","author":"JL Neul","year":"2023","unstructured":"Neul JL, Benke TA, Marsh ED, Suter B, Silveira L, Fu C, et al. Top caregiver concerns in Rett syndrome and related disorders: data from the US natural history study. J Neurodev Disord. 2023;15(1):33.","journal-title":"J Neurodev Disord"},{"issue":"3","key":"9591_CR3","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1152\/jn.00944.2015","volume":"115","author":"FS Lo","year":"2016","unstructured":"Lo FS, Blue ME, Erzurumlu RS. Enhancement of postsynaptic GABAA and extrasynaptic NMDA receptor-mediated responses in the barrel cortex of Mecp2-null mice. J Neurophysiol. 2016;115(3):1298\u2013306.","journal-title":"J Neurophysiol"},{"issue":"10","key":"9591_CR4","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ar.21380","volume":"294","author":"ME Blue","year":"2011","unstructured":"Blue ME, Kaufmann WE, Bressler J, Eyring C, O\u2019driscoll C, Naidu S, et al. Temporal and regional alterations in NMDA receptor expression in Mecp2-null mice. Anat Rec (Hoboken). 2011;294(10):1624\u201334.","journal-title":"Anat Rec (Hoboken)"},{"issue":"2","key":"9591_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1476-5381.1985.tb12922.x","volume":"84","author":"NL Harrison","year":"1985","unstructured":"Harrison NL, Simmonds MA. Quantitative studies on some antagonists of N-methyl D-aspartate in slices of rat cerebral cortex. Br J Pharmacol. 1985;84(2):381\u201391.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"9591_CR6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1016\/j.biopsych.2015.08.018","volume":"79","author":"A Patrizi","year":"2016","unstructured":"Patrizi A, Picard N, Simon AJ, Gunner G, Centofante E, Andrews NA, et al. Chronic administration of the N-methyl-D-aspartate receptor antagonist ketamine improves rett syndrome phenotype. Biol Psychiat. 2016;79(9):755\u201364.","journal-title":"Biol Psychiat"},{"issue":"40","key":"9591_CR7","doi-asserted-by":"publisher","first-page":"13860","DOI":"10.1523\/JNEUROSCI.2159-12.2012","volume":"32","author":"M Kron","year":"2012","unstructured":"Kron M, Howell CJ, Adams IT, Ransbottom M, Christian D, Ogier M, et al. Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment. J Neurosci. 2012;32(40):13860\u201372.","journal-title":"J Neurosci"},{"issue":"7354","key":"9591_CR8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature10130","volume":"475","author":"AE Autry","year":"2011","unstructured":"Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011;475(7354):91\u20135.","journal-title":"Nature"},{"issue":"6","key":"9591_CR9","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/hmg\/ddq563","volume":"20","author":"S Ricciardi","year":"2011","unstructured":"Ricciardi S, Boggio EM, Grosso S, Lonetti G, Forlani G, Stefanelli G, et al. Reduced AKT\/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum Mol Genet. 2011;20(6):1182\u201396.","journal-title":"Hum Mol Genet"},{"key":"9591_CR10","unstructured":"Welham SJ, Thorpe V, Katz DM, Zuberi SM. Reduction in seizure frequency, improved motor and cognitive skills associated with use of NMDA receptor antagonist ketamine in Rett Syndrome. In: 2017 British Pediatric Neurology Association Annual Meeting. Cambridge, UK."},{"issue":"2","key":"9591_CR11","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1192\/bjp.bp.115.165498","volume":"208","author":"RA Schoevers","year":"2016","unstructured":"Schoevers RA, Chaves TV, Balukova SM, aan het Rot M, Kortekaas R. Oral ketamine for the treatment of pain and treatment-resistant depression\u2020. Br J Psychiatry. 2016;208(2):108\u201313.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"9591_CR12","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jpeds.2012.12.077","volume":"163","author":"AL Bredlau","year":"2013","unstructured":"Bredlau AL, McDermott MP, Adams HR, Dworkin RH, Venuto C, Fisher SG, et al. Oral ketamine for children with chronic pain: a pilot phase 1 study. J Pediatr. 2013;163(1):194\u2013200.e1.","journal-title":"J Pediatr"},{"issue":"4","key":"9591_CR13","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1542\/peds.90.4.537","volume":"90","author":"JD Tobias","year":"1992","unstructured":"Tobias JD, Phipps S, Smith B, Mulhern RK. Oral ketamine premedication to alleviate the distress of invasive procedures in pediatric oncology patients. Pediatrics. 1992;90(4):537\u201341.","journal-title":"Pediatrics"},{"key":"9591_CR14","first-page":"1","volume":"19","author":"N Murphy","year":"2023","unstructured":"Murphy N, Tamman AJF, Lijffijt M, Amarneh D, Iqbal S, Swann A, et al. Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial. Neuropsychopharmacol. 2023;19:1\u20138.","journal-title":"Neuropsychopharmacol"},{"issue":"7","key":"9591_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.biopsych.2012.03.029","volume":"72","author":"BR Cornwell","year":"2012","unstructured":"Cornwell BR, Salvadore G, Furey M, Marquardt CA, Brutsche NE, Grillon C, et al. Synaptic potentiation is critical for rapid antidepressant response to ketamine in treatment-resistant major depression. Biol Psychiatry. 2012;72(7):555\u201361.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"9591_CR16","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41386-021-01242-9","volume":"47","author":"M Lijffijt","year":"2022","unstructured":"Lijffijt M, Murphy N, Iqbal S, Green CE, Iqbal T, Chang LC, et al. Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. Neuropsychopharmacology. 2022;47(5):1088\u201395.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"9591_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/ana.26948","volume":"96","author":"JN Saby","year":"2024","unstructured":"Saby JN, Mulcahey PJ, Benke TA, Peters SU, Standridge SM, Lieberman DN, et al. Electroencephalographic correlates of clinical severity in the natural history study of RTT and related disorders. Ann Neurol. 2024;96(1):175\u201386.","journal-title":"Ann Neurol"},{"issue":"1","key":"9591_CR18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s11689-019-9275-z","volume":"11","author":"KJ Roche","year":"2019","unstructured":"Roche KJ, LeBlanc JJ, Levin AR, O\u2019Leary HM, Baczewski LM, Nelson CA. Electroencephalographic spectral power as a marker of cortical function and disease severity in girls with Rett syndrome. J Neurodev Disord. 2019;11(1):15.","journal-title":"J Neurodev Disord"},{"issue":"7","key":"9591_CR19","first-page":"28","volume":"4","author":"J Busner","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"issue":"13","key":"9591_CR20","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1177\/0883073815579707","volume":"30","author":"JL Neul","year":"2015","unstructured":"Neul JL, Glaze DG, Percy AK, Feyma T, Beisang A, Dinh T, et al. Improving treatment trial outcomes for Rett syndrome: the development of Rett-specific anchors for the clinical global impression scale. J Child Neurol. 2015;30(13):1743\u20138.","journal-title":"J Child Neurol"},{"issue":"6","key":"9591_CR21","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1352\/1944-7558-125.6.493","volume":"125","author":"M Raspa","year":"2020","unstructured":"Raspa M, Bann CM, Gwaltney A, Benke TA, Fu C, Glaze DG, et al. A psychometric evaluation of the motor-behavioral assessment scale for use as an outcome measure in Rett syndrome clinical trials. Am J Intellect Dev Disabil. 2020;125(6):493\u2013509.","journal-title":"Am J Intellect Dev Disabil"},{"issue":"8","key":"9591_CR22","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/1469-7610.00236","volume":"43","author":"RH Mount","year":"2002","unstructured":"Mount RH, Charman T, Hastings RP, Reilly S, Cass H. The Rett Syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome. J Child Psychol Psychiatry. 2002;43(8):1099\u2013110.","journal-title":"J Child Psychol Psychiatry"},{"issue":"8","key":"9591_CR23","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/sleep\/23.8.1d","volume":"23","author":"JA Owens","year":"2000","unstructured":"Owens JA, Spirito A, McGuinn M. The Children\u2019s Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. Sleep. 2000;23(8):1043\u201351.","journal-title":"Sleep"},{"issue":"4","key":"9591_CR24","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s10803-017-3034-3","volume":"47","author":"JB Lane","year":"2017","unstructured":"Lane JB, Salter AR, Jones NE, Cutter G, Horrigan J, Skinner SA, et al. Assessment of caregiver inventory for Rett syndrome. J Autism Dev Disord. 2017;47(4):1102\u201312.","journal-title":"J Autism Dev Disord"},{"issue":"8","key":"9591_CR25","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1093\/bja\/53.8.805","volume":"53","author":"IS Grant","year":"1981","unstructured":"Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of I.M. and oral ketamine. Br J Anaesth. 1981;53(8):805\u201310.","journal-title":"Br J Anaesth"},{"key":"9591_CR26","unstructured":"R Core Team. R: A language and environment for statistical computing. Vienna: R foundation for Statistical Computing; 2023. Available from:\u00a0https:\/\/www.R-project.org\/."},{"issue":"4","key":"9591_CR27","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jama.2015.19394","volume":"315","author":"MA Detry","year":"2016","unstructured":"Detry MA, Ma Y. Analyzing repeated measurements using mixed models. JAMA. 2016;315(4):407.","journal-title":"JAMA"},{"issue":"6","key":"9591_CR28","doi-asserted-by":"publisher","first-page":"e4794","DOI":"10.7717\/peerj.4794","volume":"23","author":"XA Harrison","year":"2018","unstructured":"Harrison XA, Donaldson L, Correa-Cano ME, Evans J, Fisher DN, Goodwin CED, et al. A brief introduction to mixed effects modelling and multi-model inference in ecology. PeerJ. 2018;23(6):e4794.","journal-title":"PeerJ"},{"issue":"366","key":"9591_CR29","doi-asserted-by":"publisher","first-page":"l4378","DOI":"10.1136\/bmj.l4378","volume":"31","author":"K Dwan","year":"2019","unstructured":"Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ. 2019;31(366):l4378.","journal-title":"BMJ"},{"issue":"340","key":"9591_CR30","doi-asserted-by":"publisher","first-page":"c869","DOI":"10.1136\/bmj.c869","volume":"24","author":"D Moher","year":"2010","unstructured":"Moher D, Hopewell S, Schulz KF, Montori V, G\u00f8tzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;24(340):c869.","journal-title":"BMJ"},{"issue":"26","key":"9591_CR31","doi-asserted-by":"publisher","first-page":"e3984","DOI":"10.1097\/MD.0000000000003984","volume":"95","author":"O Rubinstein","year":"2016","unstructured":"Rubinstein O, Barkan S, Breitbart R, Berkovitch S, Toledano M, Weiser G, et al. Efficacy of oral ketamine compared to midazolam for sedation of children undergoing laceration repair. Medicine (Baltimore). 2016;95(26):e3984.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"9591_CR32","doi-asserted-by":"publisher","first-page":"e000717","DOI":"10.1136\/bmjpo-2020-000717","volume":"4","author":"C Fu","year":"2020","unstructured":"Fu C, Armstrong D, Marsh E, Lieberman D, Motil K, Witt R, et al. Consensus guidelines on managing Rett syndrome across the lifespan. BMJ Paediatr Open. 2020;4(1):e000717.","journal-title":"BMJ Paediatr Open"},{"issue":"8","key":"9591_CR33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/ijnp\/pyy032","volume":"21","author":"SM Shadli","year":"2018","unstructured":"Shadli SM, Kawe T, Martin D, McNaughton N, Neehoff S, Glue P. Ketamine effects on EEG during therapy of treatment-resistant generalized anxiety and social anxiety. Int J Neuropsychopharmacol. 2018;21(8):717\u201324.","journal-title":"Int J Neuropsychopharmacol"},{"issue":"1","key":"9591_CR34","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13229-021-00425-x","volume":"12","author":"CL Wilkinson","year":"2021","unstructured":"Wilkinson CL, Nelson CA. Increased aperiodic gamma power in young boys with Fragile X Syndrome is associated with better language ability. Mol Autism. 2021;12(1):17.","journal-title":"Mol Autism"},{"issue":"3","key":"9591_CR35","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1007\/s13311-021-01132-4","volume":"18","author":"C Armstrong","year":"2021","unstructured":"Armstrong C, Marsh ED. Electrophysiological biomarkers in genetic epilepsies. Neurotherapeutics. 2021;18(3):1458\u201367.","journal-title":"Neurotherapeutics"},{"issue":"185","key":"9591_CR36","doi-asserted-by":"publisher","first-page":"106996","DOI":"10.1016\/j.eplepsyres.2022.106996","volume":"1","author":"C Armstrong","year":"2022","unstructured":"Armstrong C, Zavez A, Mulcahey PJ, Sogawa Y, Gotoff JM, Hagopian S, et al. Quantitative electroencephalographic analysis as a potential biomarker of response to treatment with cannabidiol. Epilepsy Res. 2022;1(185):106996.","journal-title":"Epilepsy Res"},{"issue":"9","key":"9591_CR37","doi-asserted-by":"publisher","first-page":"e44799","DOI":"10.1371\/journal.pone.0044799","volume":"7","author":"M Scheidegger","year":"2012","unstructured":"Scheidegger M, Walter M, Lehmann M, Metzger C, Grimm S, Boeker H, et al. Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action. PLoS One. 2012;7(9):e44799.","journal-title":"PLoS One"},{"issue":"2","key":"9591_CR38","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.neuron.2015.03.023","volume":"86","author":"MV Lombardo","year":"2015","unstructured":"Lombardo MV, Pierce K, Eyler L, Barnes CC, Ahrens-Barbeau C, Solso S, et al. Different functional neural substrates for good and poor language outcome in autism. Neuron. 2015;86(2):567\u201377.","journal-title":"Neuron"},{"issue":"4","key":"9591_CR39","doi-asserted-by":"publisher","first-page":"fcac197","DOI":"10.1093\/braincomms\/fcac197","volume":"4","author":"JN Saby","year":"2022","unstructured":"Saby JN, Mulcahey PJ, Zavez AE, Peters SU, Standridge SM, Swanson LC, et al. Electrophysiological biomarkers of brain function in CDKL5 deficiency disorder. Brain Commun. 2022;4(4):fcac197.","journal-title":"Brain Commun"}],"container-title":["Journal of Neurodevelopmental Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09591-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11689-025-09591-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11689-025-09591-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:15:07Z","timestamp":1737692107000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneurodevdisorders.biomedcentral.com\/articles\/10.1186\/s11689-025-09591-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9591"],"URL":"https:\/\/doi.org\/10.1186\/s11689-025-09591-y","relation":{},"ISSN":["1866-1955"],"issn-type":[{"value":"1866-1955","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"18 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Food and Drug Administration, by the institutional review boards at each participating site, and was conducted in accordance with the principles of the Declaration of Helsinki and Good Clinical Practice. Appropriate written informed consent for study participation was obtained prior to completing any study procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KC has no competing interests. EBK has no competing interests. DNL has acted as a consultant for Acadia Pharmaceuticals, Neurogene, and Taysha Gene Therapies. He has been a Site PI for industry sponsored trials from Acadia Pharmaceuticals, GW Pharmaceuticals, Anavex Life Sciences, and Neurogene. He has received research support from RSRT. TAB has received research funding from GRIN2B Foundation, the International Foundation for CDKL5 Research, Loulou Foundation, the National Institutes of Health, and Simons Foundation; consultancy for Alcyone, AveXis, GRIN Therapeutics, GW Pharmaceuticals, the International Rett Syndrome Foundation, Marinus Pharmaceuticals, Neurogene, Ovid Therapeutics, Takeda Pharmaceutical Company Limited and Taysha; clinical trials with Acadia Pharmaceuticals Inc., GW Pharmaceuticals, Marinus Pharmaceuticals, Neurogene, Ovid Therapeutics, and Rett Syndrome Research Trust; all remuneration has been made to his department. CF has been a site investigator for industry sponsored clinical trials from Zogenix pharmaceuticals, Acadia pharmaceuticals, GW pharmaceuticals, Neurogene, and Taysha. AP was a site investigator for Acadia Pharmaceuticals and is a consultant for Acadia, Neurogene, and Taysha Gene Therapies. BS has received research funding from the NIH, IRSF, and the Blue Bird Circle; he has provided consultancy for IONIS pharmaceuticals, Neurogene, and Taysha; clinical trials with Acadia Pharmaceuticals Inc., Marinus Pharmaceuticals, Neurogene, and the Rett Syndrome Research Trust. EDM has acted as a consultant for Stoke therapeutics, Acadia Pharmaceuticals, and Novartis Pharmaceuticals. He has been a Site PI for industry sponsored trials for Stoke Theraputics, Acadia Pharmaceuticals, GW Pharmaceuticals, Zogenix Pharmaceuticals, Marinus Pharmaceuticals, Takeda Pharmaceuticals and Epygenic Pharmaceuticals. He has received research support from the NIH, Penn Orphan Disease center, RettSyndrome.org, RSRT, and International CDKL5 Research Foundation. DM has no competing interests. RLC has no competing interests. JLN has acted as a consultant for Acadia Pharmaceuticals, Alycone Pharmaceuticals, AveXis, GW Pharmaceuticals, Hoffmann-La Roche, IONIS Pharmaceuticals, Neurogene, Newron Pharmaceuticals, Ovid Therapeutics, Taysha Gene Therapies, and Ultragenyx. He has been a site PI for industry sponsored clinical research for Acadia Pharmaceuticals, GW Pharmaceuticals, IONIS Pharmaceuticals, Newron Pharmaceuticals. He has received research support from the National Institutes of Health, International Rett Syndrome Foundation, and RSRT. JvH has no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4"}}